Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$110.45 USD

110.45
389,055

+0.42 (0.38%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $110.46 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

ImmunoGen to Push Leukemia Candidate into Phase I Trial

ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.

    Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%

    Genocea Biosciences (GNCA) was a big mover last session, as the company saw its shares rise almost 25% on the day amid huge volumes.

      Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 12.1% Higher

      Rigel Pharmaceuticals (RIGL) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.

        Synergy Pharmaceuticals (SGYP) Surges: Stock Moves 12.1% Higher

        Synergy Pharmaceuticals (SGYP) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.

          3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

          The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.

            Jazz Pharmaceuticals, O'Reilly Automotive and Tesla highlighted as Zacks Bull and Bear of the Day

            Jazz Pharmaceuticals, O'Reilly Automotive and Tesla highlighted as Zacks Bull and Bear of the Day

              Kevin Cook headshot

              Bull of the Day: Jazz Pharmaceuticals (JAZZ)

              Trading at just 11X next year's $13 EPS, this innovator is just getting started fighting cancer with new FDA approvals and partnerships

                Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group

                Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group

                  Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule

                  ImmunoGen (IMGN) and Jazz Pharma announced a strategic collaboration to develop and commercialize antibody-drug conjugate products.

                    ImmunoGen (IMGN) in Focus: Stock Moves 17.3% Higher

                    ImmunoGen (IMGN) was a big mover last session, as the company saw its shares rise over 17% on the day amid huge volumes.

                      5 Excellent Value Stocks Based on Low PEG Ratio

                      While P/E alone fails to identify a true value stock, PEG helps find the intrinsic value of a stock.

                        Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session

                        Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session, as the company saw its shares rise over 9% on the day.

                          Ironwood Pharma's Combination Gout Drug Gets FDA Approval

                          Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.

                            Swarup Gupta headshot

                            Rally Set to Resume: Buy These 5 Value Picks on the Dip

                            Morgan Stanley believes that conditions for a Bull Run remain in place.

                              Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer

                              Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.

                                Endo International (ENDP) Jumps: Stock Rises 6.9%

                                Endo International (ENDP) was a big mover last session, as the company saw its shares rise almost 7% on the day amid huge volumes.

                                  Jounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% Higher

                                  Jounce Therapeutics, Inc. (JNCE) moved big last session, as its shares jumped over 7% on the day.

                                    Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact

                                    Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.

                                      Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?

                                      Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.

                                        AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

                                        AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

                                          Why Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report?

                                          Jazz Pharmaceuticals (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                            Jazz Pharma Sleep Disorder Candidate Positive in Phase III

                                            Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy results from studies evaluating its lead pipeline candidate, JZP-110, in adult patients with excessive sleepiness (ES) associated with narcolepsy and obstructive sleep apnea (OSA).

                                              Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review

                                              Jazz Pharmaceuticals plc (JAZZ) announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA.

                                                BioLineRx Makes Regulatory Submission for Trial of BL-8040

                                                BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).

                                                  Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales

                                                  Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.